Fundraising Fox
Abiologics
26 employees on LinkedIn · 1 known investors
Find your way into Abiologics
Sign up to see every warm intro you have to Abiologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abiologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Founders & leadership
AK
Avak KahvejianChairman (Founder / founding CEO)Avak Kahvejian was involved in conceiving and launching platform companies at Flagship Pioneering that leveraged new biological mechanisms and biotechnologies before founding Abiologics.
M
MikeChief Innovation Officer & Co-Founder
JD
Jaclyn DunphyCo-Founder & Senior Director of Strategy and Research OperationsCo-founder and Senior Director of Strategy and Research Operations at Abiologics, where she helped originate the company's scientific approach to designer D-protein therapeutics. Abiologics uses computational design to create protein-inspired molecules called Synteins intended to serve as a new class of therapeutics.
MM
Maria-Chiara MagnoneChief Scientific OfficerShe has held executive roles in pharmaceuticals and academia-pharma partnerships, with expertise in drug discovery, translational sciences, and clinical development, with prior focus on chronic kidney disease and precision medicine approaches in cardiovascular and metabolic disease.
Investors · 1
Frequently asked questions
- What does Abiologics do?
- Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
- Who founded Abiologics?
- Abiologics was founded by Avak Kahvejian, Mike, Jaclyn Dunphy.
- Who are Abiologics's investors?
- Abiologics's investors include Flagship Pioneering.